List of Excipients in API acalabrutinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing acalabrutinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | CALQUENCE | acalabrutinib | 0310-0512 | CELLULOSE, MICROCRYSTALLINE | 2036-07-01 |
| AstraZeneca Pharmaceuticals LP | CALQUENCE | acalabrutinib | 0310-0512 | FD&C BLUE NO. 2 | 2036-07-01 |
| AstraZeneca Pharmaceuticals LP | CALQUENCE | acalabrutinib | 0310-0512 | FERRIC OXIDE YELLOW | 2036-07-01 |
| AstraZeneca Pharmaceuticals LP | CALQUENCE | acalabrutinib | 0310-0512 | GELATIN | 2036-07-01 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for acalabrutinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
acalabrutinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COPOVIDONE K25-31
acalabrutinib drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2
acalabrutinib drug variants containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
acalabrutinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
acalabrutinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
acalabrutinib drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
acalabrutinib drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
acalabrutinib drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
acalabrutinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
acalabrutinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES
acalabrutinib drug variants containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
acalabrutinib drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
acalabrutinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
acalabrutinib drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
acalabrutinib drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
Excipient focus: STARCH, CORN
acalabrutinib drug variants containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
acalabrutinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
acalabrutinib drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-3512 |
| >Company | >Ingredient | >NDC |
acalabrutinib drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | acalabrutinib | 0310-0512 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links